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overall group (33% vs. 20%; p< 0.0001) and versus the atorvastatin group (34% vs. 
24%; p < 0.0001). ConClusions: Propensity score-matched analysis of high-risk 
patients initiating statins indicated that rosuvastatin was significantly more likely 
to reduce LDL-C compared with all other statins grouped together and compared 
with atorvastatin alone in this real world patient population.
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objeCtives: To compare the relative effectiveness and safety of all stroke preven-
tion agents in patients with atrial fibrillation (AF) through a systematic review and 
network meta-analyses. Methods: A search of MEDLINE, EMBASE, and CENTRAL 
was conducted (through December 2013) to identify Phase III randomized controlled 
trials of AF patients, comparing any two of the following agents: placebo, aspirin, 
aspirin and clopidogrel combination therapy (A+C), adjusted-dose warfarin (target 
INR 2.0-3.0), dabigatran (110 mg and 150 mg), rivaroxaban, apixaban, and edoxaban 
(high and low doses). We conducted fixed-effects Bayesian network meta-analyses 
to generate relative effectiveness estimates for the outcomes of interest (all stroke, 
ischemic stroke, myocardial infarction, overall mortality, major bleeding, intrac-
ranial hemorrhage, and fatal bleeding). For each outcome, agents were ranked 
according to their likelihood of being the best option. Results: We identified 12 
studies, comprising 81,771 patients. Compared to warfarin, dabigatran 150 mg (RR 
0.65, 95% CI 0.52-0.82) and apixaban (RR 0.80, 95% 0.66-0.96) reduced the risk of 
all strokes. Dabigatran 150 mg was also more effective than warfarin at reducing 
ischemic stroke risk (RR 0.77, 95% CI 0.59 – 0.99). All anticoagulants were more effec-
tive than A+C, aspirin and placebo at reducing the risk of ischemic and all strokes. 
All treatments were associated with a lower risk of major bleeding than warfarin, 
except for dabigatran 150 mg, rivaroxaban, A+C, and aspirin. Dabigatran 150 mg 
was most likely to be ranked best at reducing ischemic stroke risk, and low-dose 
edoxaban as best at reducing major bleeding risk. ConClusions: Anticoagulants 
effectively reduce the risk of ischemic and all strokes in AF patients, and are more 
effective than antiplatelets. Some novel anticoagulants are associated with lower 
stroke and/or major bleeding risk than warfarin. In addition to a drug’s safety and 
effectiveness, individual treatment should consider the patient’s underlying stroke 
and bleeding risk profile.
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objeCtives: Patients with atrial fibrillation (AF) and a previous stroke or tran-
sient ischaemic attack (TIA) have a high risk of stroke and may have a different 
baseline risk than patients without previous stroke or TIA, which may act as a 
treatment effect modifier. Therefore, the comparative efficacy of new oral antico-
agulants (NOACs) in terms of stroke or systemic embolism (SE) was assessed for 
the subgroup of patients with a previous stroke or TIA. Methods: A Bayesian net-
work meta-analysis (NMA) was performed for patients with previous stroke or TIA 
from three pivotal randomized controlled trials: ARISTOTLE, RE-LY, and ROCKET-AF, 
which compared apixaban, dabigatran, and rivaroxaban to warfarin, respectively. 
Parametric survival functions were used to model the hazard ratios (HR) over time 
for the compared interventions, and the difference in the shape and scale param-
eters of these functions was synthesized and indirectly compared. Results were 
compared to an analysis of constant HRs as well as to previous NMAs for this sub-
group. Results: The time-varying HRs for the treatments versus warfarin suggest 
that each NOAC is at least as efficacious as warfarin with respect to stroke and SE. 
The HR for dabigatran 150mg was fairly constant over time (range: 0.80-0.68). The 
HR for dabigatran 110mg decreased slightly over time (range: 1.82-0.40), whereas 
the HRs increased slightly over time for rivaroxaban (range: 0.61-1.34) and apixaban 
(range: 0.62-0.94). ConClusions: Based on the NMA of stroke or SE among patients 
with AF and a prior stroke or TIA, dabigatran 150mg and apixaban are expected to be 
comparable to warfarin; dabigatran 110mg is expected to be comparable to warfarin 
for the first 16 months and more efficacious up until 30 months; rivaroxaban is 
expected to more efficacious than warfarin for the first 4 months, and comparable 
to warfarin thereafter.
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objeCtives: In order to indirectly compare new oral anticoagulants (NOACs) for 
patients with atrial fibrillation (AF), several network meta-analyses (NMAs) have 
compared the number of patients with stroke or systemic embolism (SE) at study 
end. The aim of the present analysis was to assess the comparative efficacy of 
NOACs over the entire duration of the studies, including changes in compara-
tive efficacy over time, using the published cumulative hazard rates. Methods: 
A Bayesian NMA was performed using a fractional polynomial model synthesiz-
ing data from three pivotal randomized controlled trials: ARISTOTLE, RE-LY, and 
ROCKET-AF, which evaluated apixaban, dabigatran, and rivaroxaban, respectively, 
versus warfarin. Parametric survival functions were used to model the hazard rate 
over time for the compared interventions and the difference in the shape and 
scale parameters of these functions was synthesized and indirectly compared. 
The efficacy of NOACs was evaluated and compared to constant HRs from previ-
ous NMAs. Results: The time-varying hazard ratios (HRs) versus warfarin suggest 
that each NOAC is at least as efficacious as warfarin with respect to stroke and SE. 
The HR for dabigatran 110mg was fairly constant over time (range: 0.92-0.90). The 
HR for dabigatran 150mg decreased slightly over time (range: 0.78-0.56), whereas 
the HRs increased slightly over time for rivaroxaban (range: 0.59-1.17) and apixaban 
(range: 0.55-1.11). The HRs for each treatment comparison versus warfarin were 
transformed into cumulative hazard rates per treatment. ConClusions: Based on 
the NMA of stroke or SE among the intention to treat population with AF, dabigatran 
110mg is expected to be comparable to warfarin; dabigatran 150mg is expected to 
be comparable to warfarin for the first 5 months and more efficacious up until 30 
months; rivaroxaban and apixaban are expected to more efficacious than warfarin 
for the first 11 and 12 months, respectively, and comparable to warfarin thereafter.
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objeCtives: Despite the known benefit of low-density lipoprotein cholesterol 
(LDL-C) goal attainment of less than 70 mg/dL in a reduced risk of cardiovascular 
events, its effectiveness in acute coronary syndrome patients in Thailand is limited. 
This study aimed to assess the effect of LDL-C goal attainment on first composite 
cardiovascular outcomes. Methods: A retrospective cohort study was conducted 
using medical charts of patients who were hospitalized for acute coronary syndrome 
and were treated with statins at a tertiary care hospital in Thailand between 2009 
and 2012. After admission, patients were followed from the date of LDL-C goal 
assessment until the first event of composite cardiovascular outcomes (myocardial 
infarction, stroke, death). Median follow-up time was 544 days (interquartile range: 
224-887 days). Cox proportional hazard models were used to determine the effect 
of LDL-C goal attainment on the cardiovascular outcomes. Results: A total of 405 
patients were included. Mean age was 65 years (60% males). Twenty-seven percent 
of the patients attained a LDL-C goal of < 70 mg/dL, 38% had LDL-C between 70 
and 99 mg/dL and 35 % had LDL-C ≥ 100 mg/dL. Forty-six patients experienced a 
composite cardiovascular outcome. Patients achieving a LDL-C of < 70 mg/dL was 
associated with a lower composite cardiovascular outcome compared to patients 
with a LDL-C ≥ 100 mg/dL (adjusted HR= 0.41; 95% CI= 0.18 – 0.93; p-value= 0.034). 
Patients with a LDL-C between 70-99 mg/dL had a lower composite cardiovascular 
outcome compared to patients with a LDL-C ≥ 100 mg/dL but was not statistically 
significant (adjusted HR= 0.72; 95%CI= 0.37 – 1.42; p-value= 0.346). ConClusions: 
Acute coronary syndrome patients who received statins and achieved a LDL-C of 
< 70 mg/dL were more likely to have less cardiovascular outcomes, confirming the 
data from clinical trials that “the lower LDL-C the better”. Improvements in goal 
attainment for LDL-C are encouraging.
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objeCtives: Tachyarrhythmias is a significant burden to a variety of cardiovas-
cular conditions and increased rates of stroke, death. The aim of this study was 
to critically evaluate the current evidence on the use of cryocatheter ablation (CA) 
compared with radiofrequency catheter ablation (RFCA) in patients with tachyar-
rhythmias. Methods: We searched potentially relevant studies using electronic 
databases such as Ovid-Medline, Ovid-EMBASE, Cochrane library, and two local 
medical databases through April 2013. Two independent reviewers extracted data 
from each study using a standardized form. Disagreements between reviewers 
were resolved by discussion or in consultation with a third reviewer. The quality of 
the selected studies was assessed using the Cochrane risk of bias for randomized 
controlled trials (RCTs). A fixed-effects model was used to combine trials and the 
dichotomous data were presented as relative risk (RR) with 95% confidence intervals 
(CI). Results: A total of 9 RCTs representing 1,202 patients were included. Their 
methodological quality was mostly poor. In 3 trials of atrial flutter, cryoablation, 
in comparison with RFCA, did not result in statistically significant difference in 
freedom from atrial flutter (RR 0.97, 95% CI 0.90-1.05, P= 0.43, I2= 0%). The incidence 
of freedom from atrial fibrillation was 80% in the cryoablation group compared with 
63.3% in the RFA group; this difference was not significant (RR 1.26, 95% CI 0.91-1.75, 
P= 0.16). In paroxysmal supraventricular tachycardias (PSVT), cryoablation signifi-
cantly decreased freedom from AVNRT or clinical recurrence (RR 0.95, 95% CI 0.91-
0.98, P= 0.003, I2= 0%). Major complications were not reported in the trials and the 
incidence of complications did not reported significant different. ConClusions: 
There is limited evidence to confirm the relative advantages and disadvantages of 
cryoablation versus radiofrequency ablation in patients with tachyarrhythmias. 
Further rigorous RCTs with long-term follow up that overcome the many limitations 
of the current evidence are warranted.
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meta-analySiS of Safety of dabigatRan and waRfaRin foR atRial 
fibRillation
Aggarwal S., Kumar S., Segal J.
Novel Health Strategies, Bethesda, MD, USA
objeCtives: Atrial fibrillation (AF) is an irregular and often rapid heart rate that 
commonly causes poor blood flow to the body. Dabigatran and Warfarin have shown 
safety and efficacy for treatment of AF. The objective of this study was to conduct 
meta-analysis and present evidence for safety of Dabigatran versus Warfarin for 
treatment of AF. Methods: For this meta-analysis we included randomized con-
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trolled trials (RCTs) evaluating Dabigatran for the treatment of AF. We included stud-
ies that were: (1) a RCT in humans; (2) an investigation of patients with nonvalvular 
atrial fibrillation; (3) an evaluation of dabigatran compared with warfarin or each 
other; and (4) a report of results of stroke or systemic emboli and major bleeding. A 
systematic literature search for dabigatran trials was undertaken for the databases 
Pubmed, Embase, Biosis, Google Scholar, and Cochrane. Data was collected for the 
study size, interventions, year and total bleeding events. For meta-analysis, random 
effects and fixed effects models were used to obtain cumulative statistics. Results: 
Two RCTs with a total of 12,268 patients were identified. The pooled event rate 
for Dabigatran for total bleeding events was 31.9% (95% CI 31%-33%). The pooled 
response rate for Warfarin for total bleeding events was 35.1% (95% CI 34%-37%). The 
cumulative relative risk for total bleeding events with Dabigatran versus Warfarin 
was 0.91 (95% CI 0.89-0.93). ConClusions: Meta-analysis shows Dabigatran has a 
slightly lower rate of total bleeding events compared to Warfarin.
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objeCtives: The objective of the study was to determine costs and clinical out-
comes of antihypertensive treatment patients taking amlodipine or telmisar-
tan. Methods: This year long prospective observational study was carried out 
at cardiology OPD of a private tertiary health care hospital. The patients over 20 
years of age, either sex, with clinically diagnosed hypertension (JNC VII) receiving 
either telmisartan (40 & 80 mg OD) or amlodipine (5 mg OD or BD) were followed for 
a period of at least 8 weeks after baseline assessment. An attempt made to under-
stand the direct costs involved. The primary outcome measured was difference in 
SBP and DBP after 8 weeks of treatment vs. baseline BP. Only the direct costs were 
included. Results: Of 250 patients studied, 120 belonged to the amlodipine and 
130 to the telmisartan group. 150 had a family history of hypertension. The aver-
age systolic and diastolic BP was 153.90±15.7 and 93.36±7.1 mmHg, respectively. 
Age, weight, height, BMI, Baseline SBP and DBP and duration of hypertension did 
not differ in between amlodipine and telmisartan group. The prevalence of CAD 
was more in male patients; and, the prevalence of diabetes was more in female 
patients. The average reduction in SBP was amlodipine and telmisartan group 
was 17.92±10.2mmHg and 18.48±13.6 mmHg. The average DBP reduction found in 
amlodipine and telmisartan group were 9.45±7.3 and 10.3±6.9 mmHg. However, 
at the end of the minimal follow up period, there was no statistically significant 
difference found in reduction of DBP. BP control was significantly different in 
diabetic and non-diabetic patients. The average cost of drugs per mmHg reduction 
of BP was INR973 and INR812 in amlodipine and telmisartan arms, respectively, 
in non-diabetic hypertensive patients on monotherapy. ConClusions: Despite 
its limitations, the results offer indicative evidence using the real-time Asian 
Indian patients.
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hoSPitalization in PatientS with ChRoniC heaRt failuRe: thailand
Chinwong S., Heamloha R., Triprasertwong W., Chinwong D., Phrommintikul A.
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objeCtives: Current guidelines recommend a combination of ACEIs/ARBs, beta-
blockers and aldosterone antagonists for the treatment of chronic heart disease; 
however, previous studies have found minimal use of these medications. This 
study aimed to evaluate the physicians’ adherence to treatment guidelines and 
to explore the association between adherence to guidelines and re-hospitalization 
in patients with chronic heart failure in Thailand. Methods: This retrospec-
tive cohort study collected data from systolic heart failure patients who received 
treatment from a tertiary university-affiliated hospital between January 2008 and 
December 2010 and were followed-up for 2 years. The evaluation of the physicians’ 
adherence to treatment guidelines in prescribing ACEIs/ARBs, beta-blockers and 
aldosterone antagonists (primary endpoint) were conducted by using a Guideline 
Adherence Indicator (GAI-3; classified as low, medium and high) according to the 
recommendation of guidelines. The secondary endpoint was re-hospitalization for 
CHF during the follow-up period. Results: Of 155 patients, more patients were 
prescribed beta-blockers (65.8%) than ACEIs/ARBs (50.7%) and aldosterone antag-
onists (20.0%). Twenty-five, 47 and 28 percent of patients were classified as low, 
medium and high GAI-3, respectively. The rate of re-hospitalization was lower in 
patients with a high GAI-3 score compared to patients with a medium or low GAI-3 
score (79.1 vs. 90.4 vs. 94.9, per 100 person-years, respectively). Multivariable Cox 
regression analysis (adjusted by sex, age, NYHA Functional Class and comorbidity) 
found that patients with high and medium GAI-3 scores had a lower risk of re-
hospitalization compared with low GAI-3 score (high GAI-3 score:adjusted HR 0.184, 
95%CI:0.093-0.367,p< 0.001; medium GAI-3 score: adjusted HR 0.436, 95%CI:0.238-
0.797,p= 0.007). ConClusions: Physicians’ adherence to treatment guidelines for 
systolic heart failure was not optimal. Some patients did not receive medications 
following the guidelines’ recommendation. Our results suggested that using medi-
cations following treatment guidelines was an important factor to reduce the risk 
of re-hospitalization from heart failure.
PCV26
the uSe of Pillbox and time in theRaPeutiC Range among new uSeRS 
of waRfaRin: a PRoPeCtiVe CohoRt Study
Dumas S.1, Rouleau-Mailloux É.2, Bouchama N.1, Lahcene H.1, Tardif J.C.2, Talajic M.2,  
Dubé M.P.2, Perreault S.3
1Université de Montréal, Montreal, QC, Canada, 2Montreal Heart Institute, Beaulieu-Saucier 
Université de Montréal Pharmacogenomics Centre, Montréal, QC, Canada, 3Université de 
Montréal, Montréal, QC, Canada
objeCtives: Warfarin, a widely prescribed oral anticoagulant, is well known to have a 
narrow therapeutic index. Many studies confirmed that adherence helps to achieve a 
stabilization of the INR, but little data is available on the impact of the use of a pillbox. 
The objective of this study is to evaluate the association between the use of a pillbox 
among new warfarin-users and time in therapeutic range (TTR). Methods: This 
study was based on a prospective cohort of new warfarin-users which aims to assess 
the genetic, clinical and environmental risk factors associated with the effectiveness 
and safety of warfarin. Demographic and clinical data were collected among a sub-
group of 702 patients who began the treatment between May 1st, 2010 and Aug. 31st, 
2012 at one of 18 hospitals in Quebec, Canada. Patients were followed-up each three 
months up to a year after the initiation of warfarin. Our outcome was the TTR and 
it was tested using a mixed linear model to allow for repeated measures. Results: 
Mean age was 70.0 ± 11.6, 60.1% were men, 79% had atrial fibrillation as a primary 
indication for warfarin, 67.9% had hypertension and 61.1% had dyslipidemia. Of these 
patients, 47.2%, 53.1%, 56.1% and 60.4% used a pillbox at 3, 6, 9 and 12 months, respec-
tively. Patients who used their own pillbox (approximately 75% of pillbox users) had 
a higher TTR than non-users (3.7%, p= 0.03). These results were adjusted for the INR 
target, age, number of concomitant drugs and patient-reported dose of warfarin as 
these covariates were significantly associated with the outcome. ConClusions: 
There is a significant association between the use of a pillbox prepared by the patient 
and a higher TTR. The use of this device may improve the stability of patients taking 
warfarin, but the clinical significance of this finding is arguable.
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objeCtives: Diuretics are drugs of first choice in the treatment of hypertension. 
The aim of this study was to analyze the consumption of diuretics in Serbia in the 
period from 2008 to 2012 year. Methods: The data about the use of drugs were 
taken from the Agency for Drugs and Medical Devices of the Serbia. Results: The 
use of diuretics during the observed period in Serbia is quite small and it ranged 
from 5 to 6% of the total consumption of all drugs from the C group. Furosemide was 
the most frequently used diuretic from 2008-2010. In the observed period consump-
tion of furosemide ranged about 61 % of the total consumption of all diuretics. On 
the second place in consupmtion during first three years of the study was indapa-
mide. Indapamid records decline in consumption in next two years. In 2011. and 
2012. hydrochlorothiazide takes second place in consumption and marks a possitive 
trend. In 2012. it ranged 7.92 DDD/1000 inh/day. Spironolactone takes the fourth 
position in the first three years. During the 2011. and 2012. consumption of spirono-
lactone has increased and took the third position in consumption. Consumption 
of all other diuretics was small. ConClusions: In Serbia, in the observed period, 
consumption of diuterics were uneven. It is two to three times lower in compari-
son with the consumption of diuretics in Norway and Finland. This research was 
supported by Provincial Secretariat for Science and Technological Development, 
Autonomous Province of Vojvodina project No 114-451-2458/2011 and by Ministry 
of Science, Republic of Serbia, project no 41012.
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objeCtives: Patients with a history of a cardiovascular (CV) disease are at high risk 
of developing secondary major adverse cardiac events (MACE), including death, non-
fatal myocardial infarction (MI), stroke, symptomatic pulmonary embolism, CV and 
all-cause hospitalization, and bleeding. The objective is to review the epidemiology 
and burden of MACE in patients with coronary artery disease (CAD) or peripheral 
arterial disease (PAD) in Europe, Asia, Latin America and Canada. Methods: A 
comprehensive search was conducted in PubMed, EMBASE, Cochrane and other 
relevant sites. 460 full-text articles, published between 2003 and 2013, were 
reviewed. Results: MACE was more prevalent in CAD/PAD patients compared to 
matched controls (> 2-fold higher). Proportions of CAD patients who have had MI, 
stroke, or bleeding were 1.4%–3.0%, 1.24% and 0.81%, respectively. For PAD patients, 
these proportions were 1.37%–13.7%, 0.4%–5.2%, and 1.3%, respectively. Compared 
to individuals with no CV disease, MACE incidence in CAD or PAD patients was 
increased by at least two-fold, ranging from 18.1%–32.3% for all-cause death, 
12.1%–18.9% for CV death, 8.2%–17.3% for MI and 6.8%–11.3% for stroke. In patients 
with CAD, evidence of MACE was reported within 30 days of primary percutane-
ous coronary intervention and incidence increased over time. The main risk fac-
tors for MACE in CAD/PAD patients included increased oxidative stress in coronary 
and peripheral arteries, diabetes, and chronic kidney disease. Limited information 
was found on the economic and humanistic burden of MACE in CAD/PAD patients. 
Available data showed that MACE occurrence increased hospitalization rates and 
associated costs, in addition to worsening patients’ quality of life. ConClusions: 
Although gaps in the literature were identified, this assessment showed that the 
risk of MACE is substantial among CAD/PAD patients and imposes a considerable 
burden. Development of preventive measures is warranted.
PCV29
RateS of aCute CoRonaRy eVentS and all CauSe moRtality in 
PatientS with Stable CoRonaRy aRteRy diSeaSe (Cad) afteR 
myoCaRdial infaRCtion and additional CaRdioVaSCulaR RiSk 
faCtoRS
DeVore S1, Mellstrom C.2, Hunt P.R.3, Kern D.M.4, Tunceli O.4, Wu B.4, Westergaard M.2, 
Hammar N.2
1AstraZeneca, Wilmington, DE, USA, 2AstraZeneca, Mölndal, Sweden, 3Evidera, Lexington, MA, 
USA, 4HealthCore, Inc., Wilmington, DE, USA
